ADARx Pharmaceuticals (ADRX) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ADARx Pharmaceuticals is the larger company by market cap ($1.85 billion vs $1.69 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | ZBIO |
|---|---|---|
| Share price | $17.28 | $25.99 |
| Market cap | $1.85B | $1.69B |
| 1-day change | -0.29% | -7.77% |
| YTD return | — | -22.39% |
| 1-year return | — | +35.16% |
| EPS (TTM) | $-1.16 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.21 | $44.60 |
| 52-week low | $16.64 | $13.50 |
| Distance from 52-week high | -25.55% | -41.73% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +84.22% |
| Average volume | 1.34M | 735.12K |
| Shares outstanding | 106.80M | 65.18M |
| Employees | 100 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
ADRX vs ZBIO FAQ
Which is bigger, ADARx Pharmaceuticals or Zenas BioPharma?
ADARx Pharmaceuticals (ADRX) is larger, with a market capitalization of $1.85B compared with $1.69B for Zenas BioPharma (ZBIO).
Are ADARx Pharmaceuticals and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.